IRLAB Therapeutics AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported negative sales was SEK 1.19 million compared to sales of SEK 12.18 million a year ago. Negative revenue was SEK 1.19 million compared to revenue of SEK 12.32 million a year ago. Net loss was SEK 34.99 million compared to SEK 33.17 million a year ago. Basic loss per share from continuing operations was SEK 0.67 compared to SEK 0.64 a year ago. Diluted loss per share from continuing operations was SEK 0.67 compared to SEK 0.64 a year ago.
For the full year, sales was SEK 5.68 million compared to SEK 61.14 million a year ago. Revenue was SEK 5.72 million compared to SEK 61.28 million a year ago. Net loss was SEK 177.84 million compared to SEK 113.41 million a year ago. Basic loss per share from continuing operations was SEK 3.43 compared to SEK 2.19 a year ago.